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Abstract: A hybridoma against the nucleoside m6A has been obtained from 
mouse spleen. This hybridoma was named H65 and it secretes monoclonal 
antibodies anti-m6A. The competition assays showed that the monoclonal 
antibody was highly specific for m6A nucleoside. 
 
 
Modified nucleosides are a common feature of RNA molecules (for a 
review see ref. 1). In some cases, these modified nucleosides are 
characteristic of some RNA molecules and they have been used to classify 
the RNAs. One example is the nucleoside trimethylguanosine, which is a 
hallmark of UsnRNAs (1). 
Specific nucleosides are modified post-transcriptionally, but in many 
cases little is known about the enzymes and the sequences or structural 
requirements for the modification of a specific nucleoside. N6-
methyladenosine (m6A) is present at internal positions of tRNA, rRNA, 
mRNA and snRNA molecules (1). The consensus sequence Pu(G/A)AC(U/A)- 
A being methylated- in the pre-mRNAs has been described as the 
recognition site for the methyltransferase (2). In each pre-mRNA molecule, 
one in every three adenosines are usually methylated (2-5). Recently, using 
a rabbit reticulocyte translation system it has been shown that internal m6A 
increases the in vitro translation efficiency of dihydrofolate reductase 
messenger RNA (6). The human N6-Adenosine Methyltransferase of the pre-
mRNA substrate has been partially purified (7) and it consists of at least 
three subunits of 30, 200 and 875 kDa. By further purification of the 
fraction containing the 200 kDa unit, a 70 kDa protein has been isolated, 
which when sequenced turned out to be a subunit of the human N6-
Adenosine Methyltransferase (8). Little is known about whether the same 
methyltransferase methylates all RNAs or there are specific 
methyltransferases for each class of RNAs. The methylated sequences found 
in the snRNA, tRNA and rRNA molecules are not similar to those in the 
mRNAs (9-11). Furthermore, the enzyme that methylates the adenosine in 
the U6snRNA is different to the mRNA-methyltransferase (11). 
 
 
 
FIG. 1. Immune response of the mice to m6A nucleoside conjugated to BSA. 
Two Balb/c mice (referred as B4 and B5 in the figure) were immunized with 
m6A-BSA following Bochning et al. (13). Twenty days after the first 
immunization, some blood was taken from the mouse tail and sera obtained 
by centrifugation of the blood. Sera from each animal was diluted 1/50 to 
1/10000 in PBS/T and analyzed by ELISA plates coated with m6A-KLH. Pre-
immune sera (referred as NIS in the figure) from each animal was also 
diluted and analyzed in parallel. Only the OD values obtained with 85 pre-
immune serum are indicated in the figure. B4 and B5 serum showed a titer 
of around 1/8000 and 1/6000, respectively. 
 
The recognition of the adenosine methylation by such a biological tool 
as an antibody, which is able to distinguish both between methylated and 
nonmethylated adenosine, and between methylation in different ring 
positions of nucleosidednucleotides or even hypermethylation, is an 
important tool to characterize this post-transcriptional mechanism. 
Polyclonal antibodies antim6A that recognize the m6A of UsnRNAs have been 
described (12). Here we describe a monoclonal antibody anti-msA that 
specifically recognizes m6A. 
Two Balb/c mice (referred as B4 and B5) were immunized with the 
m6A-BSA conjugate as described by Bochning et al. 1987. Fig. 1 shows the 
titers obtained with the sera from both mice 20 days after the initial 
injection and coating the ELISA-wells with the m6A-KLH conjugate. 
The figure also shows the results obtained with the non-immune sera 
(sera obtained from each mice before immunization). Sera from B4 and B5 
showed titers of 118000 and 116000, respectively. The reaction of the sera 
with the m6A-KLH conjugate was inhibited when the diluted sera was 
competed with free m6A nucleoside (result not shown). This suggests that 
both animals produce antibodies specific for m6A, and that they also have 
serum titers high enough to try to obtain a hybridoma from their B 
lymphocytes. 
Spleenocytes from B4 mouse (B5 mouse died a few days before the 
fusion experiment) were fused with NS1 myeloma cells. Fourteen days after 
the hybridoma fusion, the supernatants of the hybridomas were screened 
with m6A-KLH conjugate and 24 positive wells were selected. Out of these 
clones, only 13 remained stable and reacted with the m6A-KLH conjugate. 
Three of these hybridomas were cloned three times by limiting dilution, and 
one stably hybridoma was expanded and referred to as H65. H65 
hybridoma stable secretes monoclonal antibodies (IgG1, κ) anti-m6A after 
freezing and defrosting procedures. The reaction of the H65 monoclonal 
antibody with the m6A-KLH conjugate is inhibited using free m6A 
nucleoside. 
Figure 2 shows that the inhibition of the reaction increases when 
larger amounts of free m6A nucleoside were added to the solution, thus 
indicating that the antibody specifically recognizes the m6A nucleoside of the 
conjugate. Cross-reactions with other nucleosides/ nucleotides were studied 
by competitive ELISA assays with the following nucleosides/ nucleotides: 
m6A (N6-methyladenosine); A (adenosine); m2
6,6A (N6,N6-
dimethyladenosine); m1A (1-methyladenosine); Am (2'-O-
methyladenosine); m6Ade (N6-methyladenine); m7G (7-methylguanosine), 
ATP and GTP (also showed in Figure 2). Only m6A resulted in an inhibitory 
effect at a concentration of 0.01-50 nmols (figure 2); whereas m6Ade 
showed a very low inhibitory effect (10%) with highest concentration of the 
inhibitor (50 nmols). All the other competitors studied did not inhibit the 
binding of the antibody to the m6A-KLH conjugate. 
This property of the H65 monoclonal antibody distinguishes itself 
from the rabbit polyclonal antibody R1280 obtained in 1987 (12). R1280 
significantly cross-reacted with Am (12) whereas H65 monoclonal antibody 
specifically recognizes 6-monomethyladenosine, since neither adenosine (A) 
nor N6,N6-dimethyladenosine (m2
6,6A) inhibited the reaction between the 
monoclonal antibody and the m6A-KLH conjugate. This second property also 
makes H65 different to R1280, as this polyclonal antibody clearly cross-
reacted with both m6Ade and m2
6,6A nucleosides (12). 
 
 
FIG. 2. The specificity of the monoclonal H65 antibody was showed by 
competition ELISA assay with m6A, m2
6,6A, m1A, Am, m6Ade, m7G 
nucleosides and with the ATP, GTP nucleotides. The ELISA plates 
were coated with m6A-KLH at a concentration of 13 µg/ml, which was 
maintained in all the competition assays. 100 µl of the H65 
hybridoma supernatant was mixed with increasing amount (0, 0.01, 
0.1, 0.5, 1, 5, 10 to 50 nmols in 10 µl of PBS buffer) of each 
nucleoside. A control reaction with no nucleoside was also performed 
(0 nmols in the figure). The percentage of inhibition was calculated 
comparing the OD values for each reaction with that obtained with 0 
nmols of free nucleoside. An inhibition of around 70% was obtained 
with 35 nmols of free nucleoside m6A, and 10% of inhibition with 50 
nmols of the nucleoside m6Ade. Other nucleosides/nucleotides did not 
inhibit the antibody reaction in this range of concentrations and they 
are all plotted together in the line marked as "others". 
 
In summary, adenosines methylated at different ring or ribose 
positions showed a higher rate of competition with the reaction of R1280 
and m6Aconjugate than with that of H65 and the conjugate.  
The specificity of the H65 monoclonal antibody was further studied by 
binding assays with a nucleoside column. The nucleoside column was 
prepared by covalent binding of the m6A nucleoside ribose to the amino 
groups of EAH Sepharose 4B resin (13). This method avoided the presence 
of the carrier proteins (either BSA or KLH) during the binding of the H65 
monoclonal antibody to m6A nucleoside. H65 monoclonal antibodies from 
either hybridoma supernatant or ascite fluids clearly bound to m6A-EAH 
Sepharose 4B resin and bound monoclonal antibodies were then eluted by 
competition with free m6A nucleoside (Figure 3).  
This result again indicates that the binding is specific and 
independent of the carrier protein conjugated to the m6A nucleoside. The 
purified monoclonal antibody reacted with the m6A-KLH conjugate in ELISA 
plates and the reaction was inhibited by free nucleoside. The purified anti-
m6A monoclonal showed the same properties than the crude antibody (both 
from the supernatant and the ascites fluid) when tested in competition 
ELISA assays (data not shown). 
 
FIG. 3. The anti-m6A nucleoside antibodies from the H65 hybridoma bound 
to m6A nucleoside columns and were later eluted by competition with free 
m6A nucleoside. Lane 1 and 2 show respectively the crude supernatant 
fraction of the H65 hybridoma before the immunoaffinity chromatography 
and the purified monoclonal antibody after loading the supernatant on the 
m6Acolumn and eluting with free m6A nucleoside. H and L mean heavy and 
light chains of the IgGs. 
 
Finally, a nuclear extract from HeLa cells was immunoprecipitated 
with the monoclonal antibody H65. 100 p1 of hibridoma supernatant was 
used (corresponding to 0.2-1 vg of antibody) in this assay. An 
antitrimethylguanosine monoclonal antibody (1 0 pg) that 
immunoprecipitates UsnRNAs, was also used as a positive control. The 
results obtained are shown in figure 4. 
As can be seen in the figure 4, H65 immunoprecipitates both 
U4snRNA and a small amount of U2snRNA. Both of these UsnRNAs contain 
the m6A modification. U2snRNA is not easily immunoprecipitated with the 
antibody, since the m6A modification is not very accessible to the antibody 
in this extract (our unpublished results). Besides the antibody did not 
immunoprecipitate U5snRNA (figure 4), which does not have m6A 
modification. The presence of U1 snRNA in the anti-m6A immunoprecipitates 
has also been reported with other anti- m6A antibodies (12). These results 
indicate that our antibody recognizes the m6A modification in RNA. 
In summary, here we report a monoclonal antibody that specifically 
recognizes m6A nucleoside. The antibody did not recognize either A or 
m2
6,6A. 
 
FIG. 4. lrnrnunoprecipitation of UsnRNAs with the monoclonal antibody H65. 
Lanes: 1, nonrelated monoclonal antibody (negative control); 2, monoclonal 
antibody Ab-1 antitrimethylguanosine (14) (10 µg of antibody) and 3, 
monoclonal H65 anti-rn6A (100 µl of supernatant, 0.2-1 µg of antibody). The 
band marked with an arrowhead corresponds to 5.8 S ribosomal RNA and is 
caused by an inespecific reaction of both antibodies (antitrirnethylguanosine 
and anti-rm6A) in these conditions, and it is due to the fact that this RNA is 
a very good substrate for pCp labeling. As pCp labeling does not allow to 
quantify RNAs (since different RNAs are differentially labeled with this 
technique) the intensity of these bands does not reflect the real amount of 
RNA in the band. 
 
 EXPERIMENTAL SECTION 
 
m6A-Conjugates and nucleosides/nucleotides 
The nucleoside m6A (Sigma) was conjugated either to the carrier KLH 
(keyhole limpet hemocyanin) or to BSA (bovine serum albumin) following 
the method described by Erlanger and Beiser (15). Other nucleosides/ 
nucleotides used in this work were purchased from Sigma. 
 
Mice immunization and fusions 
Two female Balb/c mice were immunized with 400 µg of the m6A-BSA 
conjugate following the method described by Boching et al. (immunogen in 
complete adjuvant on day 0, and immunogen in incomplete adjuvant on 
days 20, 28, 33, 34 and 35) (13). Both mice rendered good antibody titers 
(see Fig. 1 in results). The spleenocytes isolated from both mice on day 36 
were fused to NS1 myeloma cells (13). 
 
Screening of anti-m6A positive clones and hybridoma cloning 
14 days after the spleenocyte fusion, the supernatants were screened 
with ELISA plates coated with m6A-KLH conjugate. Hybridomas in positive 
wells were cloned by limiting dilution. One clone, referred as H65, remained 
stable after three cloning steps by limiting dilution. This clone was also 
stable after freezing/defrosting treatments. 
 
ELlSAs with the m6A-KLH conjugate. 
Each ELISA well was coated with 50 µg of m6A-KLH solution (13 µg 
/ml) in PBS (20 mM KH2P04 pH 7.4, 140 mM NaCl, 0.02% NaN3) and 
incubated overnight at 4 ºC. On the next day, the plates were washed three 
times with PBS/T (PBS with 0.1% Tween 20). The wells were then 
incubated with the antibody solutions: either 50 µl of mice sera diluted 1/50 
to 1/10000 in PBS/T, 100 µl of hybridoma supernatants diluted 1/2 in PBS/T 
or 100 µl of non-diluted supernatants without dilution. The ELISA plates 
were then incubated for 90 min at room temperature. Then, the plates were 
washed three times with PBS/T and each well was incubated for 2 h at room 
temperature with 50 µl of anti-mouse IgG conjugated to alkaline-
phosphatase and diluted 1/1000 in PBS/T. The plates were washed three 
times with PBS/T and incubated with the substrate solution (50 mM 
Na2C03/NaHC03 pH 9.5, 2 mM MgCl2 and 1 mg/ml p-nitrophenyl-
phosphate). The plates were measured at 405-450 nm 30 rnin after 
substrate addition. 
 
ELISA competition-assay. 
Each ELISA well was coated with 50 µl of m6A-KLH solution (13 µg 
/ml) in PBS (20 mM KH2P04 pH 7.4, 140 mM NaCl, 0.02% NaN3) and 
incubated overnight at 4 ºC. On the next day, the plates were washed three 
times with PBS/T. Wells were saturated with a solution containing 0.5% 
teleostean gelatin in PBS for 1 h at room temperature. The competition 
solution was prepared as follows: 100 µl of the hybridoma supernatant was 
incubated with different amounts of each nucleoside (from 0 to 50 nmols, 
each quantity dissolved in 10 µl of PBS), in different tubes for 1 h at room 
temperature. After saturation, the ELISA wells were washed three times 
with PBS/T. Each well was then incubated with one of the competition 
solutions (110 µl) for 1 h at room temperature. From this point, the ELISA 
plates were treated as described above. 
 
lmmunoprecipitation assay. 
lmmunoprecipitation assay was performed as previously described 
(16). pCp labeling of the UsnRNAs was performed as indicated in the 
previous publication (16). 
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